▶ 調査レポート

製薬契約×組織の世界市場見通し2023年-2029年

• 英文タイトル:Pharmaceutical Contract X Organization Market, Global Outlook and Forecast 2023-2029

Market Monitor Globalが調査・発行した産業分析レポートです。製薬契約×組織の世界市場見通し2023年-2029年 / Pharmaceutical Contract X Organization Market, Global Outlook and Forecast 2023-2029 / MRC2312MG15450資料のイメージです。• レポートコード:MRC2312MG15450
• 出版社/出版日:Market Monitor Global / 2023年12月
• レポート形態:英文、PDF、102ページ
• 納品方法:Eメール(納期:3営業日)
• 産業分類:医療
• 販売価格(消費税別)
  Single User¥487,500 (USD3,250)▷ お問い合わせ
  Enterprise User¥731,250 (USD4,875)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
当調査レポートは次の情報を含め、世界の製薬契約×組織市場規模と予測を収録しています。・世界の製薬契約×組織市場:売上、2018年-2023年、2024年-2029年
・世界の製薬契約×組織市場:販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の製薬契約×組織市場は2022年に000Mドルと評価され、予測期間中に000%のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「CRO」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。

製薬契約×組織のグローバル主要企業は、LabCorp、 IQVIA、 Covance、 PPD (Thermo Fisher Scientific)、 ICON、 Lonza、 Parexel、 Aenova、 Siegfried、 Recipharm、 Tigermed、 WuXi AppTec、 Pharmaron、 ChemPartner、 Asymchem、 WuXi Biologicsなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

MARKET MONITOR GLOBAL(MMG)は、製薬契約×組織のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別市場分析】

世界の製薬契約×組織市場:タイプ別、2018年-2023年、2024年-2029年
世界の製薬契約×組織市場:タイプ別市場シェア、2022年
・CRO、CMO/CDMO

世界の製薬契約×組織市場:用途別、2018年-2023年、2024年-2029年
世界の製薬契約×組織市場:用途別市場シェア、2022年
・製薬会社、バイオテクノロジー会社、ジェネリック会社、その他

世界の製薬契約×組織市場:地域・国別、2018年-2023年、2024年-2029年
世界の製薬契約×組織市場:地域別市場シェア、2022年
・北米:アメリカ、カナダ、メキシコ
・ヨーロッパ:ドイツ、フランス、イギリス、イタリア、ロシア
・アジア:中国、日本、韓国、東南アジア、インド
・南米:ブラジル、アルゼンチン
・中東・アフリカ:トルコ、イスラエル、サウジアラビア、UAE

【競合分析】

また、当レポートは主要な市場参加者の分析を提供します。
・主要企業における製薬契約×組織のグローバル売上、2018年-2023年
・主要企業における製薬契約×組織のグローバル売上シェア、2022年
・主要企業における製薬契約×組織のグローバル販売量、2018年-2023年
・主要企業における製薬契約×組織のグローバル販売量シェア、2022年

さらに、当レポートは主要企業のプロファイルを提示します。
LabCorp、 IQVIA、 Covance、 PPD (Thermo Fisher Scientific)、 ICON、 Lonza、 Parexel、 Aenova、 Siegfried、 Recipharm、 Tigermed、 WuXi AppTec、 Pharmaron、 ChemPartner、 Asymchem、 WuXi Biologics

*************************************************************

・調査・分析レポートの概要
製薬契約×組織市場の定義
市場セグメント
世界の製薬契約×組織市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の製薬契約×組織市場規模
世界の製薬契約×組織市場規模:2022年 VS 2029年
世界の製薬契約×組織市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの製薬契約×組織の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の製薬契約×組織製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分:CRO、CMO/CDMO
製薬契約×組織のタイプ別グローバル売上・予測

・用途別市場分析
用途区分:製薬会社、バイオテクノロジー会社、ジェネリック会社、その他
製薬契約×組織の用途別グローバル売上・予測

・地域別市場分析
地域別製薬契約×組織市場規模 2022年と2029年
地域別製薬契約×組織売上・予測
北米市場:アメリカ、カナダ、メキシコ
ヨーロッパ市場:ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場:中国、日本、韓国、東南アジア、インド
南米市場:ブラジル、アルゼンチン
中東・アフリカ市場:トルコ、イスラエル、サウジアラビア、UAE

・主要企業のプロファイル(企業概要、事業概要、主要製品、売上、ニュースなど)
LabCorp、 IQVIA、 Covance、 PPD (Thermo Fisher Scientific)、 ICON、 Lonza、 Parexel、 Aenova、 Siegfried、 Recipharm、 Tigermed、 WuXi AppTec、 Pharmaron、 ChemPartner、 Asymchem、 WuXi Biologics
...

This research report provides a comprehensive analysis of the Pharmaceutical Contract X Organization market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Pharmaceutical Contract X Organization market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Pharmaceutical Contract X Organization, challenges faced by the industry, and potential opportunities for market players.
The global Pharmaceutical Contract X Organization market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Pharmaceutical Contract X Organization market presents opportunities for various stakeholders, including Pharmaceutical Company, Biotechnology Company. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Pharmaceutical Contract X Organization market. Additionally, the growing consumer demand present avenues for market expansion.
The global Pharmaceutical Contract X Organization market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Key Features:
The research report on the Pharmaceutical Contract X Organization market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Pharmaceutical Contract X Organization market.
Market Overview: The report provides a comprehensive overview of the Pharmaceutical Contract X Organization market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., CRO, CMO/CDMO), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Pharmaceutical Contract X Organization market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Pharmaceutical Contract X Organization market’s trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Pharmaceutical Contract X Organization market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Pharmaceutical Contract X Organization market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Pharmaceutical Contract X Organization market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Pharmaceutical Contract X Organization market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Pharmaceutical Contract X Organization, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Pharmaceutical Contract X Organization market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Pharmaceutical Contract X Organization market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
CRO
CMO/CDMO
Market segment by Application
Pharmaceutical Company
Biotechnology Company
Generics Company
Others
Global Pharmaceutical Contract X Organization Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
LabCorp
IQVIA
Covance
PPD (Thermo Fisher Scientific)
ICON
Lonza
Parexel
Aenova
Siegfried
Recipharm
Tigermed
WuXi AppTec
Pharmaron
ChemPartner
Asymchem
WuXi Biologics
Outline of Major Chapters:
Chapter 1: Introduces the definition of Pharmaceutical Contract X Organization, market overview.
Chapter 2: Global Pharmaceutical Contract X Organization market size in revenue.
Chapter 3: Detailed analysis of Pharmaceutical Contract X Organization company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Pharmaceutical Contract X Organization in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.

レポート目次

1 Introduction to Research & Analysis Reports
1.1 Pharmaceutical Contract X Organization Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Pharmaceutical Contract X Organization Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Pharmaceutical Contract X Organization Overall Market Size
2.1 Global Pharmaceutical Contract X Organization Market Size: 2022 VS 2029
2.2 Global Pharmaceutical Contract X Organization Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Pharmaceutical Contract X Organization Players in Global Market
3.2 Top Global Pharmaceutical Contract X Organization Companies Ranked by Revenue
3.3 Global Pharmaceutical Contract X Organization Revenue by Companies
3.4 Top 3 and Top 5 Pharmaceutical Contract X Organization Companies in Global Market, by Revenue in 2022
3.5 Global Companies Pharmaceutical Contract X Organization Product Type
3.6 Tier 1, Tier 2 and Tier 3 Pharmaceutical Contract X Organization Players in Global Market
3.6.1 List of Global Tier 1 Pharmaceutical Contract X Organization Companies
3.6.2 List of Global Tier 2 and Tier 3 Pharmaceutical Contract X Organization Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global Pharmaceutical Contract X Organization Market Size Markets, 2022 & 2029
4.1.2 CRO
4.1.3 CMO/CDMO
4.2 By Type – Global Pharmaceutical Contract X Organization Revenue & Forecasts
4.2.1 By Type – Global Pharmaceutical Contract X Organization Revenue, 2018-2023
4.2.2 By Type – Global Pharmaceutical Contract X Organization Revenue, 2024-2029
4.2.3 By Type – Global Pharmaceutical Contract X Organization Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Pharmaceutical Contract X Organization Market Size, 2022 & 2029
5.1.2 Pharmaceutical Company
5.1.3 Biotechnology Company
5.1.4 Generics Company
5.1.5 Others
5.2 By Application – Global Pharmaceutical Contract X Organization Revenue & Forecasts
5.2.1 By Application – Global Pharmaceutical Contract X Organization Revenue, 2018-2023
5.2.2 By Application – Global Pharmaceutical Contract X Organization Revenue, 2024-2029
5.2.3 By Application – Global Pharmaceutical Contract X Organization Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global Pharmaceutical Contract X Organization Market Size, 2022 & 2029
6.2 By Region – Global Pharmaceutical Contract X Organization Revenue & Forecasts
6.2.1 By Region – Global Pharmaceutical Contract X Organization Revenue, 2018-2023
6.2.2 By Region – Global Pharmaceutical Contract X Organization Revenue, 2024-2029
6.2.3 By Region – Global Pharmaceutical Contract X Organization Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America Pharmaceutical Contract X Organization Revenue, 2018-2029
6.3.2 US Pharmaceutical Contract X Organization Market Size, 2018-2029
6.3.3 Canada Pharmaceutical Contract X Organization Market Size, 2018-2029
6.3.4 Mexico Pharmaceutical Contract X Organization Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe Pharmaceutical Contract X Organization Revenue, 2018-2029
6.4.2 Germany Pharmaceutical Contract X Organization Market Size, 2018-2029
6.4.3 France Pharmaceutical Contract X Organization Market Size, 2018-2029
6.4.4 U.K. Pharmaceutical Contract X Organization Market Size, 2018-2029
6.4.5 Italy Pharmaceutical Contract X Organization Market Size, 2018-2029
6.4.6 Russia Pharmaceutical Contract X Organization Market Size, 2018-2029
6.4.7 Nordic Countries Pharmaceutical Contract X Organization Market Size, 2018-2029
6.4.8 Benelux Pharmaceutical Contract X Organization Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia Pharmaceutical Contract X Organization Revenue, 2018-2029
6.5.2 China Pharmaceutical Contract X Organization Market Size, 2018-2029
6.5.3 Japan Pharmaceutical Contract X Organization Market Size, 2018-2029
6.5.4 South Korea Pharmaceutical Contract X Organization Market Size, 2018-2029
6.5.5 Southeast Asia Pharmaceutical Contract X Organization Market Size, 2018-2029
6.5.6 India Pharmaceutical Contract X Organization Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America Pharmaceutical Contract X Organization Revenue, 2018-2029
6.6.2 Brazil Pharmaceutical Contract X Organization Market Size, 2018-2029
6.6.3 Argentina Pharmaceutical Contract X Organization Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa Pharmaceutical Contract X Organization Revenue, 2018-2029
6.7.2 Turkey Pharmaceutical Contract X Organization Market Size, 2018-2029
6.7.3 Israel Pharmaceutical Contract X Organization Market Size, 2018-2029
6.7.4 Saudi Arabia Pharmaceutical Contract X Organization Market Size, 2018-2029
6.7.5 UAE Pharmaceutical Contract X Organization Market Size, 2018-2029
7 Pharmaceutical Contract X Organization Companies Profiles
7.1 LabCorp
7.1.1 LabCorp Company Summary
7.1.2 LabCorp Business Overview
7.1.3 LabCorp Pharmaceutical Contract X Organization Major Product Offerings
7.1.4 LabCorp Pharmaceutical Contract X Organization Revenue in Global Market (2018-2023)
7.1.5 LabCorp Key News & Latest Developments
7.2 IQVIA
7.2.1 IQVIA Company Summary
7.2.2 IQVIA Business Overview
7.2.3 IQVIA Pharmaceutical Contract X Organization Major Product Offerings
7.2.4 IQVIA Pharmaceutical Contract X Organization Revenue in Global Market (2018-2023)
7.2.5 IQVIA Key News & Latest Developments
7.3 Covance
7.3.1 Covance Company Summary
7.3.2 Covance Business Overview
7.3.3 Covance Pharmaceutical Contract X Organization Major Product Offerings
7.3.4 Covance Pharmaceutical Contract X Organization Revenue in Global Market (2018-2023)
7.3.5 Covance Key News & Latest Developments
7.4 PPD (Thermo Fisher Scientific)
7.4.1 PPD (Thermo Fisher Scientific) Company Summary
7.4.2 PPD (Thermo Fisher Scientific) Business Overview
7.4.3 PPD (Thermo Fisher Scientific) Pharmaceutical Contract X Organization Major Product Offerings
7.4.4 PPD (Thermo Fisher Scientific) Pharmaceutical Contract X Organization Revenue in Global Market (2018-2023)
7.4.5 PPD (Thermo Fisher Scientific) Key News & Latest Developments
7.5 ICON
7.5.1 ICON Company Summary
7.5.2 ICON Business Overview
7.5.3 ICON Pharmaceutical Contract X Organization Major Product Offerings
7.5.4 ICON Pharmaceutical Contract X Organization Revenue in Global Market (2018-2023)
7.5.5 ICON Key News & Latest Developments
7.6 Lonza
7.6.1 Lonza Company Summary
7.6.2 Lonza Business Overview
7.6.3 Lonza Pharmaceutical Contract X Organization Major Product Offerings
7.6.4 Lonza Pharmaceutical Contract X Organization Revenue in Global Market (2018-2023)
7.6.5 Lonza Key News & Latest Developments
7.7 Parexel
7.7.1 Parexel Company Summary
7.7.2 Parexel Business Overview
7.7.3 Parexel Pharmaceutical Contract X Organization Major Product Offerings
7.7.4 Parexel Pharmaceutical Contract X Organization Revenue in Global Market (2018-2023)
7.7.5 Parexel Key News & Latest Developments
7.8 Aenova
7.8.1 Aenova Company Summary
7.8.2 Aenova Business Overview
7.8.3 Aenova Pharmaceutical Contract X Organization Major Product Offerings
7.8.4 Aenova Pharmaceutical Contract X Organization Revenue in Global Market (2018-2023)
7.8.5 Aenova Key News & Latest Developments
7.9 Siegfried
7.9.1 Siegfried Company Summary
7.9.2 Siegfried Business Overview
7.9.3 Siegfried Pharmaceutical Contract X Organization Major Product Offerings
7.9.4 Siegfried Pharmaceutical Contract X Organization Revenue in Global Market (2018-2023)
7.9.5 Siegfried Key News & Latest Developments
7.10 Recipharm
7.10.1 Recipharm Company Summary
7.10.2 Recipharm Business Overview
7.10.3 Recipharm Pharmaceutical Contract X Organization Major Product Offerings
7.10.4 Recipharm Pharmaceutical Contract X Organization Revenue in Global Market (2018-2023)
7.10.5 Recipharm Key News & Latest Developments
7.11 Tigermed
7.11.1 Tigermed Company Summary
7.11.2 Tigermed Business Overview
7.11.3 Tigermed Pharmaceutical Contract X Organization Major Product Offerings
7.11.4 Tigermed Pharmaceutical Contract X Organization Revenue in Global Market (2018-2023)
7.11.5 Tigermed Key News & Latest Developments
7.12 WuXi AppTec
7.12.1 WuXi AppTec Company Summary
7.12.2 WuXi AppTec Business Overview
7.12.3 WuXi AppTec Pharmaceutical Contract X Organization Major Product Offerings
7.12.4 WuXi AppTec Pharmaceutical Contract X Organization Revenue in Global Market (2018-2023)
7.12.5 WuXi AppTec Key News & Latest Developments
7.13 Pharmaron
7.13.1 Pharmaron Company Summary
7.13.2 Pharmaron Business Overview
7.13.3 Pharmaron Pharmaceutical Contract X Organization Major Product Offerings
7.13.4 Pharmaron Pharmaceutical Contract X Organization Revenue in Global Market (2018-2023)
7.13.5 Pharmaron Key News & Latest Developments
7.14 ChemPartner
7.14.1 ChemPartner Company Summary
7.14.2 ChemPartner Business Overview
7.14.3 ChemPartner Pharmaceutical Contract X Organization Major Product Offerings
7.14.4 ChemPartner Pharmaceutical Contract X Organization Revenue in Global Market (2018-2023)
7.14.5 ChemPartner Key News & Latest Developments
7.15 Asymchem
7.15.1 Asymchem Company Summary
7.15.2 Asymchem Business Overview
7.15.3 Asymchem Pharmaceutical Contract X Organization Major Product Offerings
7.15.4 Asymchem Pharmaceutical Contract X Organization Revenue in Global Market (2018-2023)
7.15.5 Asymchem Key News & Latest Developments
7.16 WuXi Biologics
7.16.1 WuXi Biologics Company Summary
7.16.2 WuXi Biologics Business Overview
7.16.3 WuXi Biologics Pharmaceutical Contract X Organization Major Product Offerings
7.16.4 WuXi Biologics Pharmaceutical Contract X Organization Revenue in Global Market (2018-2023)
7.16.5 WuXi Biologics Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer